Syngene International
SYNGENE · Pharma > Pharmaceuticals & Drugs · Chairman: Kiran Mazumdar Shaw · MD: Jonathan Hunt · Listing date: Aug. 11, 2015 · Employees: 5437 · Bangalore · http://www.syngeneintl.com

Stock Price vs Company Growth
1d
0.6%
1w
2.5%
1m
6.9%
3m
14.5%
6m
3.4%
1y
38.2%
5y
9.2%
10y
4.6%
all
8.4%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 376 0.6%
360
450
Company Overview

Sales
3,600 Cr
Growth: 2.5%
Profit after Tax
221 Cr
Growth: -30.2%
Mid Cap
15,168 Cr
P/E: 68.4x
Industry P/E: 35.1x
Fundamentals

Sales (Cr) ₹ 3,600
Growth 2.5%
EBITDA 22.3%
P/S 4.2x
Dividend 0.2%
P/E 68.4x
Book Value ₹ 120
PEG Ratio 27.1x
ROE 4.5%
P/B 3.2x
Shareholding Pattern

Institutions
Government Pension Fund Global
1.14 %
Uti-Mid Cap Fund
1.03 %
Qualified Institutional Buyer
0.15 %
Promoters
Biocon Limited
70.1 %
Biocon Limited Employee Welfare Trust (Murali Krishnan K N And Amitava Saha)
0.32 %
Yamini R Mazumdar
0.01 %
Others
Increase    Decrease    No change
Company Profile Detailed

The company is a contract research, development, and manufacturing services company that offers a broad range of scientific services from the earliest stages of discovery to commercial supplies. This positions the Company as an end-to-end service provider within its sector.
Investors (435)
Followers (15)